GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clene Inc (NAS:CLNN) » Definitions » EV-to-FCF
中文

Clene (CLNN) EV-to-FCF : -1.32 (As of Apr. 24, 2024)


View and export this data going back to 2020. Start your Free Trial

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Clene's Enterprise Value is $40.20 Mil. Clene's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-30.50 Mil. Therefore, Clene's EV-to-FCF for today is -1.32.

The historical rank and industry rank for Clene's EV-to-FCF or its related term are showing as below:

CLNN' s EV-to-FCF Range Over the Past 10 Years
Min: -41.07   Med: -3.69   Max: -0.62
Current: -1.32

During the past 5 years, the highest EV-to-FCF of Clene was -0.62. The lowest was -41.07. And the median was -3.69.

CLNN's EV-to-FCF is ranked worse than
100% of 392 companies
in the Biotechnology industry
Industry Median: 4.22 vs CLNN: -1.32

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-24), Clene's stock price is $0.326. Clene's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.520. Therefore, Clene's PE Ratio for today is At Loss.


Clene EV-to-FCF Historical Data

The historical data trend for Clene's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clene Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
- -24.92 -6.38 -1.88 -1.16

Clene Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.88 -2.57 -2.65 -1.64 -1.16

Competitive Comparison

For the Biotechnology subindustry, Clene's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clene EV-to-FCF Distribution

For the Biotechnology industry and Healthcare sector, Clene's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Clene's EV-to-FCF falls into.



Clene EV-to-FCF Calculation

Clene's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=40.199/-30.501
=-1.32

Clene's current Enterprise Value is $40.20 Mil.
Clene's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-30.50 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Clene  (NAS:CLNN) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Clene's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.326/-0.520
=At Loss

Clene's share price for today is $0.326.
Clene's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.520.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Clene EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Clene's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Clene (CLNN) Business Description

Traded in Other Exchanges
Address
6550 South Millrock Drive, Suite G50, Salt Lake City, UT, USA, 84121
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. Its reportable segments: (1) the development and commercialization of novel clean-surfaced nanotechnology therapeutics (Drugs, and (2) the development and commercialization of dietary supplements (Supplements).
Executives
David J Matlin director
Matthew Kiernan director 500 PRINCIPIO PARKWAY WEST, SUITE 400, NORTH EAST MD 21901
Arjun Jj Desai director C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Robert Dee Etherington director, officer: Chief Executive Officer 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
John Henry Stevens director 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
Chidozie Ugwumba director 158 FILMORE STREET, DENVER CO 80206
Alison Mosca director 26 PATRIOT PLACE, SUITE 301, FOXBORO MA 02035
Jonathon Gay director 177 HUNTINGTON AVENUE, 21ST FLOOR, BOSTON MA 02115
General Resonance Llc 10 percent owner 6510 SOUTH MILLROCK DRIVE, SUITE 250, HOLLADAY UT 84121
Robert Glanzman officer: Chief Medical Officer 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
Morgan R Brown officer: Chief Financial Officer 420 CHIPETA WAY, SALT LAKE CITY UT 84108
Vallerie Mclaughlin director 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
Mark Mortenson officer: Chief Science Officer 500 PRINCIPIO PARKWAY WEST, SUITE 400, NORTH EAST MD 21901
Fiona Costello director 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
Shalom Jacobovitz director 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121